ARCHIVES

Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

On Capitol Hill: Cancer Organizations Push Congress For Payment Of Patient Care Costs In Trials

September 17, 1999

ACCP Publishes Guidelines Recommending Low-Dose CT

May 31, 2013

Article Spotlight Article

Nixon National Cancer Conference Kicks Off

December 8, 2021

Protein Patterns May Identify Ovarian Cancer Earlier

March 29, 2002

Funding opportunities: ASCO breast cancer research award; Lustgarten Foundation prostate cancer research award; NCI program announcements available.

March 5, 2004

New Staff Proposals For Comprehensive Center Recognition Considered By NCAB

January 19, 1979